Editorials and Opinions

Real-World Evidence — What Is It and What Can It Tell Us?

Can a drug manufacturer declare when a pandemic is over?

The 2020 election isn’t entirely settled, but one clear winner has emerged: the health care industrial complex.

Access and Unmet Needs of Orphan Drugs in 194 Countries and 6 Areas: A Global Policy Review With Content Analysis

Trump administration finalizes rule requiring health insurers to disclose price and cost-sharing information.

Repurposed antiviral drugs for COVID-19 –interim WHO SOLIDARITY trial results

The United States has been hit particularly hard having 20 percent of the world's infections but only 4 percent of the world population.

Over the past five years, ICER has pressured drugmakers to lower the cost of nearly 100 drugs.

First-of-its-kind examination shows how widely pharma showers campaign cash at the state level.

Pharma is showering Congress with cash, even as drug makers race to fight the coronavirus.

Much is at stake for the health of the American population in the upcoming 2020 elections. Drug pricing, a critical driver of access to medications - pending this election outcome – is on the line.

Not even a pandemic can cause drug prices to drop in America.

Evolution of the COVID-19 vaccine development landscape.

Drug pricing in America is complex.

Modèles de Prix Pour Médicaments.